Baidu
map

我国自主研发脊髓灰质炎灭活疫苗获批上市!

2017-08-30 佚名 健康时报网

国家食品药品监管总局批准了北京北生研生物制品有限公司(以下简称北生研公司)的Sabin株脊髓灰质炎灭活疫苗(以下简称IPV疫苗))生产注册申请。这是继中国医学科学院医学生物学研究所的脊髓灰质炎灭活疫苗之后,我国企业自主研发的又一个新的脊髓灰质炎灭活疫苗产品。脊髓灰质炎是一种病毒引起的极具感染性的疾病,主要影响幼童。病毒通过受污染的食物和水传播, 在肠道内繁殖,再侵袭神经系统。在少数情况下,该病可造

国家食品药品监管总局批准了北京北生研生物制品有限公司(以下简称北生研公司)的Sabin株脊髓灰质炎灭活疫苗(以下简称IPV疫苗))生产注册申请。这是继中国医学科学院医学生物学研究所的脊髓灰质炎灭活疫苗之后,我国企业自主研发的又一个新的脊髓灰质炎灭活疫苗产品。

脊髓灰质炎是一种病毒引起的极具感染性的疾病,主要影响幼童。病毒通过受污染的食物和水传播, 在肠道内繁殖,再侵袭神经系统。在少数情况下,该病可造成永久瘫痪。

目前脊髓灰质炎只能通过免疫接种预防。上世纪60年代,全国推广口服脊髓灰质炎减毒活疫苗,这项工作起到巨大成效,2000年中国被世界卫生组织确认为无脊髓灰质炎的国家。尽管如此,我国保持无脊髓灰质炎的工作仍然充满挑战,截至2012年底统计表明,全球范围内仍有3个国家存在脊灰野病毒的流行,其中与中国接壤的就有2个。世界卫生组织提出的《消灭脊髓灰质炎最后阶段战略计划(2013-2018)》(以下简称《战略计划》)的两个平行目标是消灭脊髓灰质炎野病毒和消灭疫苗衍生脊髓灰质炎。利用脊髓灰质炎灭活疫苗替代减毒活疫苗将成为全球消灭脊髓灰质炎的必由之举。

北生研公司的IPV疫苗系采用世界卫生组织提供的Sabin株脊髓灰质炎Ⅰ、Ⅱ、Ⅲ型毒株,分别接种于非洲绿猴肾传代细胞(Vero细胞)培养后收获病毒液,经浓缩、纯化和灭活后,按一定比例混合制成的三价液体疫苗。疫苗接种后可刺激机体产生抗脊髓灰质炎病毒的免疫力,预防由相应病毒毒株引起的脊髓灰质炎。该疫苗适用于2月龄(含)以上儿童的免疫接种。

此次获批上市的IPV疫苗预计将于今年10月投放市场。该疫苗的上市将会有效缓解我国脊髓灰质炎灭活疫苗短缺的局面。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1632541, encodeId=ae7d16325412d, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Wed Nov 08 13:46:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078829, encodeId=eba220e882964, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon May 28 08:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672156, encodeId=a32516e2156c2, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85966, encryptionId=177c85966dc, topicName=自主研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2c26890289, createdName=xlwang2700, createdTime=Mon Feb 05 23:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300049, encodeId=91181300049df, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483126, encodeId=17b3148312663, content=<a href='/topic/show?id=19398461920' target=_blank style='color:#2F92EE;'>#脊髓灰质炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84619, encryptionId=19398461920, topicName=脊髓灰质炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9117881304, createdName=12498c32m70暂无昵称, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238873, encodeId=01a72388e375, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Aug 31 07:12:53 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238833, encodeId=73af23883381, content=学习过了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Aug 31 00:09:19 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238818, encodeId=d9a323881839, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Aug 31 00:03:35 CST 2017, time=2017-08-31, status=1, ipAttribution=)]
    2017-11-08 weiz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1632541, encodeId=ae7d16325412d, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Wed Nov 08 13:46:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078829, encodeId=eba220e882964, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon May 28 08:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672156, encodeId=a32516e2156c2, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85966, encryptionId=177c85966dc, topicName=自主研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2c26890289, createdName=xlwang2700, createdTime=Mon Feb 05 23:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300049, encodeId=91181300049df, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483126, encodeId=17b3148312663, content=<a href='/topic/show?id=19398461920' target=_blank style='color:#2F92EE;'>#脊髓灰质炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84619, encryptionId=19398461920, topicName=脊髓灰质炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9117881304, createdName=12498c32m70暂无昵称, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238873, encodeId=01a72388e375, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Aug 31 07:12:53 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238833, encodeId=73af23883381, content=学习过了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Aug 31 00:09:19 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238818, encodeId=d9a323881839, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Aug 31 00:03:35 CST 2017, time=2017-08-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1632541, encodeId=ae7d16325412d, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Wed Nov 08 13:46:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078829, encodeId=eba220e882964, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon May 28 08:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672156, encodeId=a32516e2156c2, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85966, encryptionId=177c85966dc, topicName=自主研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2c26890289, createdName=xlwang2700, createdTime=Mon Feb 05 23:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300049, encodeId=91181300049df, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483126, encodeId=17b3148312663, content=<a href='/topic/show?id=19398461920' target=_blank style='color:#2F92EE;'>#脊髓灰质炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84619, encryptionId=19398461920, topicName=脊髓灰质炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9117881304, createdName=12498c32m70暂无昵称, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238873, encodeId=01a72388e375, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Aug 31 07:12:53 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238833, encodeId=73af23883381, content=学习过了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Aug 31 00:09:19 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238818, encodeId=d9a323881839, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Aug 31 00:03:35 CST 2017, time=2017-08-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1632541, encodeId=ae7d16325412d, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Wed Nov 08 13:46:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078829, encodeId=eba220e882964, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon May 28 08:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672156, encodeId=a32516e2156c2, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85966, encryptionId=177c85966dc, topicName=自主研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2c26890289, createdName=xlwang2700, createdTime=Mon Feb 05 23:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300049, encodeId=91181300049df, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483126, encodeId=17b3148312663, content=<a href='/topic/show?id=19398461920' target=_blank style='color:#2F92EE;'>#脊髓灰质炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84619, encryptionId=19398461920, topicName=脊髓灰质炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9117881304, createdName=12498c32m70暂无昵称, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238873, encodeId=01a72388e375, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Aug 31 07:12:53 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238833, encodeId=73af23883381, content=学习过了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Aug 31 00:09:19 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238818, encodeId=d9a323881839, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Aug 31 00:03:35 CST 2017, time=2017-08-31, status=1, ipAttribution=)]
    2017-09-01 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=1632541, encodeId=ae7d16325412d, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Wed Nov 08 13:46:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078829, encodeId=eba220e882964, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon May 28 08:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672156, encodeId=a32516e2156c2, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85966, encryptionId=177c85966dc, topicName=自主研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2c26890289, createdName=xlwang2700, createdTime=Mon Feb 05 23:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300049, encodeId=91181300049df, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483126, encodeId=17b3148312663, content=<a href='/topic/show?id=19398461920' target=_blank style='color:#2F92EE;'>#脊髓灰质炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84619, encryptionId=19398461920, topicName=脊髓灰质炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9117881304, createdName=12498c32m70暂无昵称, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238873, encodeId=01a72388e375, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Aug 31 07:12:53 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238833, encodeId=73af23883381, content=学习过了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Aug 31 00:09:19 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238818, encodeId=d9a323881839, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Aug 31 00:03:35 CST 2017, time=2017-08-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1632541, encodeId=ae7d16325412d, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Wed Nov 08 13:46:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078829, encodeId=eba220e882964, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon May 28 08:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672156, encodeId=a32516e2156c2, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85966, encryptionId=177c85966dc, topicName=自主研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2c26890289, createdName=xlwang2700, createdTime=Mon Feb 05 23:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300049, encodeId=91181300049df, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483126, encodeId=17b3148312663, content=<a href='/topic/show?id=19398461920' target=_blank style='color:#2F92EE;'>#脊髓灰质炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84619, encryptionId=19398461920, topicName=脊髓灰质炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9117881304, createdName=12498c32m70暂无昵称, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238873, encodeId=01a72388e375, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Aug 31 07:12:53 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238833, encodeId=73af23883381, content=学习过了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Aug 31 00:09:19 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238818, encodeId=d9a323881839, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Aug 31 00:03:35 CST 2017, time=2017-08-31, status=1, ipAttribution=)]
    2017-08-31 榄枷檬

    谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1632541, encodeId=ae7d16325412d, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Wed Nov 08 13:46:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078829, encodeId=eba220e882964, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon May 28 08:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672156, encodeId=a32516e2156c2, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85966, encryptionId=177c85966dc, topicName=自主研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2c26890289, createdName=xlwang2700, createdTime=Mon Feb 05 23:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300049, encodeId=91181300049df, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483126, encodeId=17b3148312663, content=<a href='/topic/show?id=19398461920' target=_blank style='color:#2F92EE;'>#脊髓灰质炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84619, encryptionId=19398461920, topicName=脊髓灰质炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9117881304, createdName=12498c32m70暂无昵称, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238873, encodeId=01a72388e375, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Aug 31 07:12:53 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238833, encodeId=73af23883381, content=学习过了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Aug 31 00:09:19 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238818, encodeId=d9a323881839, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Aug 31 00:03:35 CST 2017, time=2017-08-31, status=1, ipAttribution=)]
    2017-08-31 明天会更好!

    学习过了.谢谢分享!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1632541, encodeId=ae7d16325412d, content=<a href='/topic/show?id=aa0488034a0' target=_blank style='color:#2F92EE;'>#获批上市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88034, encryptionId=aa0488034a0, topicName=获批上市)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=820f21933891, createdName=weiz, createdTime=Wed Nov 08 13:46:00 CST 2017, time=2017-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078829, encodeId=eba220e882964, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Mon May 28 08:46:00 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672156, encodeId=a32516e2156c2, content=<a href='/topic/show?id=177c85966dc' target=_blank style='color:#2F92EE;'>#自主研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85966, encryptionId=177c85966dc, topicName=自主研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2c26890289, createdName=xlwang2700, createdTime=Mon Feb 05 23:46:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300049, encodeId=91181300049df, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483126, encodeId=17b3148312663, content=<a href='/topic/show?id=19398461920' target=_blank style='color:#2F92EE;'>#脊髓灰质炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84619, encryptionId=19398461920, topicName=脊髓灰质炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9117881304, createdName=12498c32m70暂无昵称, createdTime=Fri Sep 01 12:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238873, encodeId=01a72388e375, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Thu Aug 31 07:12:53 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238833, encodeId=73af23883381, content=学习过了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Aug 31 00:09:19 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238818, encodeId=d9a323881839, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Thu Aug 31 00:03:35 CST 2017, time=2017-08-31, status=1, ipAttribution=)]
    2017-08-31 184****9840

    学习了受益匪浅

    0

相关资讯

Lancet Infect Dis:脊髓灰质炎粘膜免疫研究

对于全球根除脊髓灰质炎目标,识别限制脊髓灰质炎病毒复制的机制是至关重要的。目前通过口服脊髓灰质炎病毒或灭活脊髓灰质炎病毒(IPV)疫苗,以及混合计划下诱导的粘膜免疫(OPV)相关研究将告诉我们不同策略的不同阻断效果。我们对来自临床试验的样本进行了研究,对不同疫苗接种计划下的肠道免疫功能进行评估(通过粪便中的中和病毒和病毒特异性IgA浓度进行评估)。 FIDEC试验中,将拉丁美洲婴儿随机分为九

尼日利亚疫情引发脊髓灰质炎策略反思

  一名儿童在接种脊髓灰质炎疫苗。图片来源:ZUMA Press Inc. 随着尼日利亚北部报告了第3起脊髓灰质炎病例,全球根除脊髓灰质炎努力的领导者不禁自问怎会在该国犯下如此严重的错误。和上个月发现的另外两起病例一样,新发病例(一名24个月大的男孩)生活在受到暴力冲突严重破坏的博尔诺州。这里也是恐怖组织——“博科圣地”的大本营。 这个毁灭性的

Lancet infect dis:在孟加拉国停用口服三价脊髓灰质病毒疫苗后脊髓灰质炎的传播情况。

2016年4月起,在全球范围内,三价口服脊髓灰质炎疫苗(tOPV)被二价I型和3型口服脊髓灰质炎疫苗(bOPV)和一剂量的灭活脊髓灰质炎病毒(IPV)所取代。对于这一改变后II型脊髓灰质炎病毒或Sabin2病毒(脊髓灰质炎病毒的一种)对于II型脊髓灰质炎的再次引入或发生的传播风险尚未完全清楚。

PLOS MED:巴基斯坦的血清型1型脊髓灰质炎发病率的危险因素和短期预测:时空分析

目前,巴基斯坦对全球消除脊髓灰质炎提供了重大挑战,巴基斯坦,在2015年报告的脊髓灰质炎中,占据了73%,并在2016年占据了54%。更好地了解导致巴基斯坦脊髓灰质炎病毒传播的危险因素和运动模式,将有助于基于证据的大规模疫苗接种计划。

Lancet Infect Dis:氢氧化铝吸附脊髓灰质炎疫苗有效预防1-3型脊髓灰质炎

接种1/10剂量的 IPV-Al疫苗2剂或3剂即可达到较好的免疫预防效果

中国卫生行业标准-脊髓灰质炎诊断(WS 294-2016)

本标准规定了脊髓灰质炎的诊断依据、诊断原则、诊断和鉴别诊断。本标准适用于全国各级各类医疗卫生机构及其工作人员对脊髓灰质炎的诊断。下载地址:下载   (需要扣积分2分, 梅斯医学APP免积分下载) 

Baidu
map
Baidu
map
Baidu
map